Doximity, Inc. (DOCS)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Doximity, Inc. (“Doximity” or “the Company”) (NYSE: DOCS). Investors who purchased Doximity securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Doximity has violated federal securities laws.

Investigation Details:

On August 8, 2023, after the market closed, Doximity reported its first quarter 2024 financial results and issued revised guidance for fiscal year 2024.  Among other items, Doximity announced that it now expects revenue in the range of $452 million to $468 million, significantly less than the Company’s prior estimate of $503 million.  On this news, Doximity’s stock price fell $7.49 per share, or 22.8%, to close at $25.30 per share on August 9, 2023.

What’s Next?

If you are aware of any facts relating to this investigation or purchased Doximity securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Why Bronstein, Gewirtz & Grossman:

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.  Our firm has recovered hundreds of millions of dollars for investors nationwide. 

Attorney advertising. Prior results do not guarantee similar outcomes.


Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]